Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
Alexandra Dreyzin, Sandhya R. Panch, Haneen Shalabi, Bonnie Yates, Steven L. Highfill, Ping Jin, David F. Stroncek, Nirali N. Shah
Abstract
expansion, persistence, incidence of toxicities, or disease response between groups with cryopreserved and fresh CAR T cells. Among 19 patients who received anti-CD19/22 CAR T cells (11 cryopreserved and 8 fresh), patients with cryopreserved cells had similar expansion, toxicity incidence, and disease response, with decreased CAR T cell persistence. Overall, our data demonstrate efficacy of cryopreserved CAR T cells as comparable to fresh infusions, supporting cryopreservation, which will be crucial for advancing the field of cell therapy.
Topics & Concepts
CryopreservationChimeric antigen receptorImmunologyCD19MedicineAndrologyAntigenImmunotherapyBiologyImmune systemCell biologyEmbryoCAR-T cell therapy researchNanowire Synthesis and ApplicationsViral Infectious Diseases and Gene Expression in Insects